Skip to main content

Advertisement

SpringerLink
Log in

Chemoimmunotherapy—towards real progress in the treatment of chronic lymphocytic leukemia

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huhn D et al. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98: 1326–1331

    Article  CAS  Google Scholar 

  2. O'Brien S et al. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19: 2165–2170

    Article  CAS  Google Scholar 

  3. Di Gaetano N et al. (2001) Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114: 800–809

    Article  CAS  Google Scholar 

  4. Schulz H et al. (2002) Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100: 3115–3120

    Article  CAS  Google Scholar 

  5. Byrd JC et al. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101: 6–14

    Article  CAS  Google Scholar 

  6. Keating MJ et al. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol [10.1200/JCO.2005.12.051]

Download references

Acknowledgements

The synopsis was written by Emma Campbell, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Director of Clinic I for Internal Medicine at Cologne University, Cologne, Germany

    Michael Hallek

Authors
  1. Michael Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Hallek.

Ethics declarations

Competing interests

Dr Hallek has received research support from Schering AG, Roche and Amgen.

Glossary

OVERALL SURVIVAL

Measured from date of randomization to date of death or last contact

PROGRESSION-FREE SURVIVAL

Time from randomization to progression, death or last follow-up

COMPLETE RESPONSE

Maintained for 2 months, as defined by the 1996 National Cancer Institute-sponsored Working Group Guidelines

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hallek, M. Chemoimmunotherapy—towards real progress in the treatment of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2, 338–339 (2005). https://doi.org/10.1038/ncponc0202

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0202

  • Springer Nature Limited

This article is cited by

Search

Navigation